PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast - John B. Buse, MD, PhD - Exploring the Science and Practice of GLP-1 Receptor Agonists: An Update on Current and Emerging Evidence

John B. Buse, MD, PhD - Exploring the Science and Practice of GLP-1 Receptor Agonists: An Update on Current and Emerging Evidence

10/30/19 • 62 min

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Previous Episode

undefined - Andrew F. Shorr, MD, MPH, MBA, FACP, FCCP - Improving the Diagnosis, Treatment, and Outcomes of Patients With HAP and VAP: A Critical Look at Current Guidelines and New Treatment Options

Andrew F. Shorr, MD, MPH, MBA, FACP, FCCP - Improving the Diagnosis, Treatment, and Outcomes of Patients With HAP and VAP: A Critical Look at Current Guidelines and New Treatment Options

Go online to PeerView.com/GBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonary and critical care medicine discusses the microbiology, diagnosis, and treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Upon completion of this activity, participants will be able to: List the pathogens commonly implicated in causing hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), Identify risk factors for multidrug-resistant HAP and VAP, Employ an evidence-based approach to readily diagnose HAP and VAP in the critical care setting, Select empiric therapy for HAP and VAP based on the local distribution of pathogens and their antimicrobial susceptibilities, as well as individual patients’ risk factors for multidrug resistance and prior microbiology data, Summarize key features and critical differences between novel antibiotics for the treatment of HAP and VAP, Optimize antibiotic selection and use (eg, dosing) in individual patients with HAP or VAP, considering current evidence and expert recommendations as well as the appropriate use of new and emerging agents

Next Episode

undefined - Roy H. Decker, MD, PhD - NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer

Roy H. Decker, MD, PhD - NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer

Go online to PeerView.com/YKQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the role of immunotherapy in multimodal management of locally advanced and early-stage lung cancer. Upon completion of this activity, participants should be better able to: Discuss how to harness the immune system in the treatment of cancer, mechanisms of action of immune checkpoint inhibitors, and rationale for use of immunotherapy in locally advanced and earlier stages of lung cancer in the context of other treatment modalities, including chemotherapy, radiotherapy, and surgery, Evaluate key clinical trial data on the efficacy and safety of immune checkpoint inhibitor–based treatment in patients with unresectable stage III NSCLC whose cancer has not progressed following concurrent chemoradiation, Summarize other key clinical trials evaluating immunotherapies and immunotherapy-based combinatorial approaches in earlier stages of lung cancer, and available evidence from these trials, Identify appropriate patients with locally advanced, unresectable NSCLC who are candidates for immunotherapy as part of multimodal therapy for stage III disease, Implement an optimal multimodal treatment plan inclusive of concurrent chemoradiotherapy and consolidation immunotherapy for appropriate patients with stage III NSCLC, considering the latest evidence, indications, recommendations, and patient needs/preferences, Manage overlapping and non-overlapping adverse effects associated with immunotherapy, radiation therapy, and chemotherapy in patients with stage III NSCLC receiving consolidation therapy with a checkpoint inhibitor following chemoradiation